MMRF ‘Laugh For Life’ Fundraising Event — On May 5, the Multiple Myeloma Research Foundation (MMRF) will host the ‘Laugh For Life’ fundraiser in New York City from 6 p.m. to 9 p.m.  The event will feature dinner, live and silent auctions, and an entertaining line up of stand-up comedians.  More information, as well as ticket purchase, may be found at the MMRF Web site.

Dacetuzumab Clinical Trials Currently Enrolling — Seattle Genetics, Inc. has announced preclinical data for dacetuzumab, an anti-CD40 monoclonal antibody currently being tested for treatment of multiple myeloma and non-Hodgkin's lymphoma. In the most recent results, dacetuzumab enhanced patient response to regimens of conventional chemotherapeutic agents, and researchers have identified a tumor mutation that helps predict which patients will respond to dacetuzumab. Two clinical trials, the first testing dacetuzumab alone and the second testing it in conjunction with Revlimid (lenalidomide) and dexamethasone (Decadron), are currently enrolling. For more information, see the Seattle Genetics, Inc. preclinical results press release.

Sign Up With LLS’s 'Team In Training' For The Nation’s Triathlon – On September 13, the Leukemia & Lymphoma Society (LLS) will host the Nation’s Triathlon, the only triathlon dedicated to fighting blood cancer, in Washington, D.C.  Although the event is already sold out, individuals can still participate by joining LLS’s 'Team in Training' (TNT) program. By signing up with TNT, participants will receive four to five months of certified coaching, race gear, and travel and lodging arrangements. For more information, see the LLS Team in Training Web site.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.